Overview

LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.

Simplify's Take

What believers are saying

• ESCAPE strategy doubles bioproduction capacity by 2025.
• Amber Plasma acquisition boosts Czech centers to 24.
• Arras site triples medication production for patient demand.

What critics are saying

• FDA bans cripple LFB USA rPRO™ proteins in 12-18 months.
• CSL Behring squeezes Europlasma's 24 centers in 6-12 months.
• Grifols captures 25% hemostasis share in 12-24 months.

What makes LFB unique

• LFB specializes in plasma-derived medicines from 1994 French state initiative.
• rPRO™ technology expresses recombinant proteins in transgenic animal milk.
• Europlasma secures plasma via 24 Central European collection centers.

Help us improve and share your feedback! Did you find this helpful?

YesNo